Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
EXEL

EXEL - Exelixis Inc Stock Price, Fair Value and News

21.95USD-0.08 (-0.36%)Delayed as of 12 Jun 2024, 10:10 am ET

Market Summary

EXEL
USD21.95-0.08
Delayedas of 12 Jun 2024, 10:10 am
-0.36%

EXEL Alerts

  • 1 major insider buys and 4 major insider sales recently.

EXEL Stock Price

View Fullscreen

EXEL RSI Chart

EXEL Valuation

Market Cap

6.4B

Price/Earnings (Trailing)

31.3

Price/Sales (Trailing)

3.48

EV/EBITDA

47.56

Price/Free Cashflow

22.95

EXEL Price/Sales (Trailing)

EXEL Profitability

EBT Margin

6.12%

Return on Equity

9.64%

Return on Assets

7.31%

Free Cashflow Yield

4.36%

EXEL Fundamentals

EXEL Revenue

Revenue (TTM)

1.8B

Rev. Growth (Yr)

4.02%

Rev. Growth (Qtr)

-11.35%

EXEL Earnings

Earnings (TTM)

205.1M

Earnings Growth (Yr)

-6.77%

Earnings Growth (Qtr)

-56.36%

Breaking Down EXEL Revenue

52 Week Range

22.17
(Low)(High)

Last 7 days

1.3%

Last 30 days

3.1%

Last 90 days

-4.5%

Trailing 12 Months

15.4%

How does EXEL drawdown profile look like?

EXEL Financial Health

Current Ratio

3.46

EXEL Investor Care

Buy Backs (1Y)

10.55%

Diluted EPS (TTM)

0.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20241.8B000
20231.7B1.7B1.8B1.8B
20221.5B1.6B1.6B1.6B
20211.0B1.2B1.3B1.4B
2020979.2M998.4M957.8M987.5M
2019855.6M909.8M956.1M967.8M
2018585.3M672.4M745.3M853.8M
2017256.9M319.7M410.0M452.5M
201643.2M71.5M123.8M191.5M
201529.6M31.0M34.6M37.2M
201426.6M21.3M22.1M25.1M
201338.6M42.7M34.8M31.3M
2012272.3M247.9M132.9M47.5M
2011178.7M163.3M237.1M289.6M
20100162.9M173.9M185.0M
2009000151.8M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Exelixis Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 04, 2024
wyszomierski jack l
sold
-182,314
22.00
-8,287
-
May 31, 2024
poste george
acquired
-
-
18,838
-
May 31, 2024
beckerle mary c
acquired
-
-
18,838
-
May 31, 2024
wyszomierski jack l
acquired
-
-
18,838
-
May 31, 2024
smith julie
acquired
-
-
10,015
-
May 31, 2024
papadopoulos stelios
acquired
-
-
18,838
-
May 31, 2024
freire maria c
acquired
-
-
18,838
-
May 31, 2024
heyman tomas j.
acquired
-
-
18,838
-
May 31, 2024
eckhardt sue gail
acquired
-
-
18,838
-
May 31, 2024
oliver bob
acquired
-
-
18,838
-

1–10 of 50

Which funds bought or sold EXEL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
added
13.05
970,000
10,035,000
0.02%
May 30, 2024
EULAV Asset Management
reduced
-6.15
-1,118,200
14,475,300
0.40%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-28,000
2,499,000
0.02%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
added
0.17
-5,880,850
633,081,000
2.87%
May 24, 2024
Cetera Investment Advisers
added
181
505,350
788,144
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
62.05
520,435
1,383,440
0.18%
May 20, 2024
EMC Capital Management
reduced
-7.55
-22,000
236,000
0.14%
May 16, 2024
Tidal Investments LLC
added
10.04
18,730
230,418
-%
May 16, 2024
Pineridge Advisors LLC
sold off
-100
-288
-
-%
May 16, 2024
Clear Point Advisors Inc.
unchanged
-
-676
61,698
0.05%

1–10 of 45

Are Funds Buying or Selling EXEL?

Are funds buying EXEL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EXEL
No. of Funds

Unveiling Exelixis Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 08, 2024
farallon capital partners, l.p.
0.8%
2,242,720
SC 13D/A
Feb 13, 2024
renaissance technologies llc
5.16%
15,615,716
SC 13G
Feb 13, 2024
vanguard group inc
10.18%
31,671,090
SC 13G/A
Jan 24, 2024
blackrock inc.
11.6%
36,013,885
SC 13G/A
Jun 02, 2023
caligan partners lp
0.28%
910,730
SC 13D/A
Jun 02, 2023
farallon capital partners, l.p.
0.7%
2,252,820
SC 13D/A
Apr 07, 2023
farallon capital partners, l.p.
0.6%
1,959,620
SC 13D/A
Mar 27, 2023
caligan partners lp
0.26%
850,000
SC 13D/A
Mar 27, 2023
farallon capital partners, l.p.
0.6%
1,959,620
SC 13D/A
Mar 20, 2023
caligan partners lp
0.26%
850,000
SC 13D

Recent SEC filings of Exelixis Inc

View All Filings
Date Filed Form Type Document
Jun 06, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading

Peers (Alternatives to Exelixis Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
56.9B
6.8B
26.49% 20.13%
-9.53
8.3
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.8B
2.0B
3.96% -18.99%
-59.59
9.88
75.20% 68.82%
15.9B
2.5B
3.50% -10.13%
77.51
6.44
13.74% 186.89%
13.4B
3.8B
12.10% -4.22%
17.92
3.54
8.58% 129.81%
MID-CAP
5.2B
524.1M
1.76% -52.84%
-12.43
9.9
394.93% 39.61%
5.1B
107.9M
-5.57% 73.81%
-9.41
48.09
54.84% -28.31%
3.4B
251.0M
-1.97% -5.04%
-11.39
13.45
73.58% -86.73%
3.1B
240.7M
11.59% -30.36%
-6.47
12.77
-1.03% -213.92%
2.5B
813.8M
-1.44% -38.93%
-1.5K
3.05
56.43% 98.83%
2.3B
996.6M
88.40% 115.04%
-5.89
2.36
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-2.38% 30.76%
28.22
4.47
60.38% -34.49%
537.6M
881.7K
17.03% 459.00%
-15.93
481.06
-77.61% 33.36%
251.6M
4.2M
-8.83% 61.83%
-2.01
60.48
-66.30% 48.24%
21.2M
2.1M
32.97% 237.68%
-0.92
7.61
-13.45% 69.54%

Exelixis Inc News

Latest updates
Defense World6 hours ago
Yahoo Finance23 May 202407:00 am

Exelixis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-11.3%425480472470409424412419356451328385270270231259227240272240215
Costs and Expenses-0.5%396398490392380472329336273334277262275246274184174163156148131
Operating Expenses------------------163156148131
  S&GA Expenses-13.3%11413113814213111911512310399.0010298.0010282.0088.0060.0063.0058.0051.0059.0060.00
  R&D Expenses-6.9%22824533323323433719919915722216314915915417711510294.0097.0082.0063.00
EBITDA Margin-1.2%0.07*0.08*0.08*0.08*0.08*0.08*0.08*0.08*0.08*0.09*0.10*0.11*---------
Income Taxes-31.8%12.0018.005.0019.008.00-1.2519.0018.0017.0023.0015.0029.00-3.62-0.26-5.9814.0011.0016.0025.0021.0015.00
Earnings Before Taxes------------125-2.0128.00-38.0281.0060.0085.0012310091.00
EBT Margin-0.9%0.06*0.06*0.06*0.07*0.07*0.07*0.07*0.07*0.07*0.08*0.09*0.10*---------
Net Income-56.4%37.0086.001.0081.0040.00-30.1773.0071.0069.0095.0038.0096.002.0028.00-32.0467.0049.0069.0097.0079.0076.00
Net Income Margin-2.2%0.11*0.11*0.05*0.10*0.09*0.11*0.19*0.18*0.20*0.16*0.13*0.08*---------
Free Cashflow2406.2%59.00-2.5610811572.0064.0010524.0014290.0069.00161---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-4.7%2,8042,9422,9773,1423,1433,0712,9612,8812,6542,6162,4482,3672,1912,1372,1112,0471,9561,8861,7851,6431,542
  Current Assets-1.9%1,2921,3181,4431,5911,6381,6191,8421,8521,8431,8351,6621,5931,4341,4451,4081,3951,1371,011972957946
    Cash Equivalents-1.3%260263397464542503677638737664598539420321336529359268243371375
  Inventory21.8%21.0017.0025.0029.0030.0033.0027.0033.0028.0027.0028.0025.0025.0021.0019.0017.0015.0013.0013.0012.0010.00
  Net PPE-1.2%12712912111511611110810910610410095.0078.0067.0056.0052.0048.0049.0049.0051.0051.00
  Goodwill0%64.0064.0064.0064.0064.0064.0064.0064.0064.0064.0064.0064.0064.0064.0064.0064.0064.0064.0064.0064.0064.00
Liabilities-0.4%676678629615588583470490360406335324279258259213208200181154157
  Current Liabilities-5.4%373394377340328324302305289338270255213205201143140143141111125
Shareholder's Equity-6.0%2,1282,2642,3482,5282,5552,4882,4912,3912,2942,2112,1122,0431,9111,8791,8521,8331,7481,6861,6041,4891,385
  Retained Earnings-49.4%-258-173-12611.006.00-34.22-4.05-77.26-147-216-311-349-445-447-475-443-510-559-628-725-804
  Additional Paid-In Capital-2.0%2,3922,4412,4872,5312,5582,5372,5132,4772,4482,4282,4222,3912,3542,3222,3212,2692,2582,2422,2292,2122,189
Shares Outstanding-2.6%295303311320324324321320320315315314---------
Float----4,700---6,831---5,680---6,400---5,731-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations551.0%69.0011.0011712184.0074.0011031.0014896.0083.0018240.0033.0018.0010256.0015876.00132162
  Share Based Compensation-21.4%19.0024.0040.0025.0017.0026.0037.0025.0020.0023.0034.0028.0035.0019.0056.0016.0014.0016.0013.0015.0013.00
Cashflow From Investing81.1%11262.0035.00-73.78-49.59-245-68.95-135-74.54-13.05-21.24-70.8462.00-29.51-20773.0033.00-130-206-142-107
Cashflow From Financing10.7%-184-206-219-1245.00-2.00-2.044.000.00-17.99-2.889.00-2.65-18.69-3.43-5.152.00-3.003.007.005.00
  Buy Backs-10.0%185206220128-----------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

EXEL Income Statement

2024-03-29
Condensed Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 29, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 425,226$ 408,788
Operating expenses:  
Cost of goods sold21,25614,315
Research and development227,689234,246
Selling, general and administrative113,984131,397
Restructuring32,8350
Total operating expenses395,764379,958
Income from operations29,46228,830
Interest income19,89419,502
Other expense, net(89)(54)
Income before income taxes49,26748,278
Provision for income taxes11,9508,250
Net income$ 37,317$ 40,028
Net income per share:  
Basic (in dollars per share)$ 0.12$ 0.12
Diluted (in dollars per share)$ 0.12$ 0.12
Weighted-average common shares outstanding:  
Basic (in shares)300,757324,420
Diluted (in shares)305,530326,279
Net product revenues  
Revenues:  
Total revenues$ 378,523$ 363,400
License revenues  
Revenues:  
Total revenues44,67638,292
Collaboration services revenues  
Revenues:  
Total revenues$ 2,027$ 7,096

EXEL Balance Sheet

2024-03-29
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 29, 2024
Dec. 29, 2023
Current assets:  
Cash and cash equivalents$ 259,561$ 262,994
Short-term investments703,695732,308
Trade receivables, net240,577237,407
Inventory21,10617,323
Prepaid expenses and other current assets67,49067,926
Total current assets1,292,4291,317,958
Long-term investments629,561728,717
Property and equipment, net127,222128,731
Deferred tax assets, net361,578361,145
Goodwill63,68463,684
Right-of-use assets and other329,278342,122
Total assets2,803,7522,942,357
Current liabilities:  
Accounts payable26,06933,768
Accrued compensation and benefits72,95893,325
Accrued clinical trial liabilities59,33771,615
Rebates and fees due to customers75,65159,619
Accrued collaboration liabilities34,70427,533
Other current liabilities104,291108,417
Total current liabilities373,010394,277
Long-term portion of operating lease liabilities201,466189,944
Other long-term liabilities101,26894,224
Total liabilities675,744678,445
Commitments and contingencies (Note 10)
Stockholders' equity:  
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued00
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 295,032 and 302,793 at March 31, 2024, and December 31, 2023, respectively295303
Additional paid-in capital2,391,8652,440,710
Accumulated other comprehensive loss(5,204)(3,750)
Accumulated deficit(258,948)(173,351)
Total stockholders’ equity2,128,0082,263,912
Total liabilities and stockholders' equity$ 2,803,752$ 2,942,357
EXEL
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
 CEO
 WEBSITEexelixis.com
 INDUSTRYBiotechnology
 EMPLOYEES1223

Exelixis Inc Frequently Asked Questions


What is the ticker symbol for Exelixis Inc? What does EXEL stand for in stocks?

EXEL is the stock ticker symbol of Exelixis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Exelixis Inc (EXEL)?

As of Tue Jun 11 2024, market cap of Exelixis Inc is 6.42 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EXEL stock?

You can check EXEL's fair value in chart for subscribers.

What is the fair value of EXEL stock?

You can check EXEL's fair value in chart for subscribers. The fair value of Exelixis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Exelixis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EXEL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Exelixis Inc a good stock to buy?

The fair value guage provides a quick view whether EXEL is over valued or under valued. Whether Exelixis Inc is cheap or expensive depends on the assumptions which impact Exelixis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EXEL.

What is Exelixis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 11 2024, EXEL's PE ratio (Price to Earnings) is 31.3 and Price to Sales (PS) ratio is 3.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EXEL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Exelixis Inc's stock?

In the past 10 years, Exelixis Inc has provided 0.202 (multiply by 100 for percentage) rate of return.